Companies › Shanghai Longwood Biopharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Infectious disease, Immunology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LW402 | – | Phase 3 | Moderate to Severe Atopic Dermatitis | Mar 2028 |
| LW231 | – | Phase 1 | Chronic HBV Infection | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07179575 | LW231 | Phase 1 | Chronic HBV Infection | Infectious disease | Mar 2027 |
| NCT07370909 | LW402 | Phase 3 | Moderate to Severe Atopic Dermatitis | Immunology | Mar 2028 |
No annotated target.
–
IR INNOVATE RESEARCH PRIVATE Institut Pasteur Prime Gene Therapeutics Hangzhou Highlightll Pharmaceutical Paradigm Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.